Status:
COMPLETED
Assessment of Neurodevelopmental Needs in Duchenne Muscular Dystrophy
Lead Sponsor:
Virginia Commonwealth University
Collaborating Sponsors:
Northwestern University
University of Rochester
Conditions:
Duchenne Muscular Dystrophy
Eligibility:
All Genders
3+ years
Brief Summary
Duchenne Muscular Dystrophy is a genetic disease that causes progressive muscle weakness. There is now substantial evidence that boys with this disease do not demonstrate age-related gains in their co...
Detailed Description
Participants will be asked to do tasks such as solve puzzles, pay attention, and remember things through the NIHTB-CB administered using an IPad as well as complete questionnaires. The NIHTB-CB will b...
Eligibility Criteria
Inclusion
- Boys with confirmed genetic mutation in the dystrophin gene
- Boys with clinical features of DMD and in whom muscle biopsy showed absence of dystrophin
- Boys with clinical features of DMD and in whom there is a family history of DMD
- Symptomatic carrier girls with DMD
- Ages 3 and above at time of study screening
Exclusion
- Care-giver unable to give consent
- Any handicap that does not allow the ability to use an IPAD
- For MRI, braces or any metal implants.
Key Trial Info
Start Date :
February 2 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05280730
Start Date
February 2 2022
End Date
September 30 2024
Last Update
August 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital of Richmond
Richmond, Virginia, United States, 23219